StanleyC.A., BakerL. Hyperinsulinism in infants and children: diagnosis and therapy. Adv Pediatr1976; 23: 315–55.
2.
BieligkS, JaffeB.M.. Islet cell tumors of the pancreas. Surg Clin North Am1995; 75: 1025–7.
3.
NortonJ.A.. Insulinoma. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg1994; 31: 89–108.
4.
Vassilopoulou-SellinR, AjaniJ. Islet cell tumors of the pancreas. Endocrinol Metab Clin North Am1994; 23: 53–64.
5.
ArnoldR. Therapeutic strategies in the management of endocrine GEP tumours. Eur J Clin Invest1990; 20(suppl): S82–90.
6.
GoodeP.N., FarndonJ.R., AndersonJ, JohnstonI, MorteJ. Diazoxide in the management of patients with insulinoma. World J Surg1986; 10: 586–92.
7.
Drug topics red book 1995.Montvale, NJ: Medical Economics, 1995: 392, 408.
8.
ParkerJ.J., AllenD.B.. Hypertrophic cardiomyopathy after prolonged diazoxide therapy for hyperinsulinism. J Pediatr1991; 118: 906–9.
9.
TsaiS, EckhauserF.E., ThompsonN.W., StrodelW.E., VinikA.I.. Perioperative use of long-acting somatostatin analog (SMS 201–995) in patients with endocrine tumors of the gastroenteropancreatic axis. Surgery1986; 100: 788–95.
10.
MatonP.N., GardnerJ.D., JensenR.T.. Use of long-acting somatostatin analog SMS 201–995 in patients with pancreatic islet cell tumors. Dig Dis Sci1989; 34(suppl): 28S–39S.
11.
SchrezenmeirJ, PleweG, SturmerW, KahalyG, OppermannD, KrauseUTreatment of APUomas with the long-acting somatostatin analogue SMS 201–995. Scan J Gastroenterol1986; 21(suppl 119): 217–22.
12.
ThorntonP.S., AlterC.A., Levitt KatzL.E., BakerL, StanleyC.A.,. Short-and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr1993; 123: 637–43.
13.
GlaserB, HirschH.J., LandauH. Persistent hyperinsulinemic hypoglycemia of infancy: long-term octreotide treatment without pancreatectomy. J Pediatr1993; 123: 644–50.
14.
KirkJMW, SilvioL.D., HindmarshP.C., BrookCGD. Somatostatin analogue in short term management of hyperinsulinism. Arch Dis Child1988; 63: 1493–4.
15.
VerschoorL, UitterlindenP, LambertsSWJ, PozoE.D.. On the use of a new somatostatin analogue in the treatment of hypoglycemia in patients with insulinoma. Clin Endocrinol1986; 25: 555–60.
16.
KvolsL.K., BuckM, MoertelC.G., SchuttA.J., RubinJ, O'ConnellM.J.Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201–995). Ann Intern Med1987; 107: 162–8.
17.
OseiK, O'DorisioT.M.. Malignant insulinoma: effects of a somatostatin analog (compound 201–995) on serum glucose, growth, and gastro-entero-pancreatic hormones. Ann Intern Med1985; 103: 223–5.
18.
GlaserB, RosierA, HalperinY. Chronic treatment of a benign insulinoma using the long-term acting somatostatin analogue SMS 201–995. Isr J Med Sci1990; 26: 16–9.
